Literature DB >> 16376803

Pleuropulmonary involvement in ankylosing spondylitis.

Abdellah El Maghraoui1.   

Abstract

Pleuropulmonary involvement was long described as an uncommon and late event in the course of ankylosing spondylitis (AS). This belief was based on studies that relied on symptoms and chest radiographs to evaluate the lungs. However, pleuropulmonary involvement in AS patients is usually asymptomatic, and the early lesions are undetectable on chest radiographs. Apical fibrosis, interstitial infiltrates, and pleural thickening were considered to be the main patterns. However, the introduction of high-resolution computed tomography (HRCT) has led to the description of many pulmonary abnormalities that are clinically silent and undetectable on plain radiographs. These abnormalities mainly affect the interstitium and have no influence on respiratory function, which is dependent on the severity of chest wall inflammation or ankylosis in recent-onset and established AS, respectively. Cytological and histological studies suggest that, in common with uveitis and aortic regurgitation, the structural lung changes shown by HRCT may be specific of AS.

Entities:  

Mesh:

Year:  2005        PMID: 16376803     DOI: 10.1016/j.jbspin.2004.05.006

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  13 in total

1.  The efficiency of inspiratory muscle training in patients with ankylosing spondylitis.

Authors:  Bilge Basakci Calik; Elif Gur Kabul; Harun Taskın; Orcin Telli Atalay; Ummuhan Bas Aslan; Murat Tascı; Fahrettin Bıcakcı; Ali Ihsan Yıldız
Journal:  Rheumatol Int       Date:  2018-06-25       Impact factor: 2.631

Review 2.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

3.  Pulmonary function in ankylosing spondylitis: association with clinical variables.

Authors:  A J L Brambila-Tapia; A D Rocha-Muñoz; L Gonzalez-Lopez; M Vázquez-Del-Mercado; M Salazar-Páramo; I P Dávalos-Rodríguez; L De la Cerda-Trujillo; M L Diaz-Toscano; P Hernandez-Cuervo; V Diaz-Rizo; D Sanchez-Mosco; J C Vazquez-Jimenez; E G Cardona-Muñoz; J I Gamez-Nava
Journal:  Rheumatol Int       Date:  2013-03-30       Impact factor: 2.631

Review 4.  Spondyloarthritis in North Africa: an update.

Authors:  Samy Slimani; Wafa Hamdi; Kawtar Nassar; Asgar Ali Kalla
Journal:  Clin Rheumatol       Date:  2021-02-09       Impact factor: 2.980

5.  Pulmonary abnormalities on high-resolution computed tomography in ankylosing spondylitis: relationship to disease duration and pulmonary function testing.

Authors:  Oya Ozdemir; Meltem Gülsün Akpınar; Fatma Inanıcı; H Zafer Hasçelik
Journal:  Rheumatol Int       Date:  2011-04-09       Impact factor: 2.631

6.  Spinal mobility, vertebral squaring, pulmonary function, pain, fatigue, and quality of life in patients with ankylosing spondylitis.

Authors:  Hyungpil Cho; Taikon Kim; Tae-Hwan Kim; Seunghun Lee; Kyu Hoon Lee
Journal:  Ann Rehabil Med       Date:  2013-10-29

7.  Ankylosing spondylitis with mycetoma case treated with oral itraconazole.

Authors:  Taha Bekci; Recep Kesli; Recep Kelsi; Emin Maden; Orhan Ozbek
Journal:  Rheumatol Int       Date:  2009-08-20       Impact factor: 2.631

8.  Bilaterally repeated spontaneous pneumothorax with ankylosing spondylitis.

Authors:  Hiroyuki Kaneda; Yukihito Saito; Miki Okamoto; Tomohiro Maniwa; Ken-ichiro Minami; Hiroji Imamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-06

9.  Prevalence and characteristics of lung involvement on high resolution computed tomography in patients with ankylosing spondylitis: a systematic review.

Authors:  Abdellah El Maghraoui; Mohamed Dehhaoui
Journal:  Pulm Med       Date:  2012-02-22

10.  The results of purified protein derivative test in ankylosing spondylitis patients: clinical features, HRCT results and relationship with TNF-blocker usage.

Authors:  Omer Nuri Pamuk; Yusuf Yesil; Salim Donmez; Ercüment Unlü; Ibrahim Hakki Köker; Necati Cakir
Journal:  Rheumatol Int       Date:  2008-08-06       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.